With its expertise in neuroscience, translational medicine, and clinical development, Eliem Therapeutics is focused on developing and commercializing innovative drug candidates to treat neuronal excitability disorders, including chronic pain, depression, epilepsy, and anxiety, to improve the quality of life of millions of patients worldwide. Eliem is headquartered in Seattle, with R&D primarily in Cambridge, UK, and is a publicly traded company (NASDAQ: ELYM).